Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.

Helmut ButzkuevenTomas KalincikFrancesco PattiMark SleeBianca Weinstock-GuttmanKatherine BuzzardOlga SkibinaRaed AlroughaniAlexandre PratMarc GirardDana HorakovaEva Kubala HavrdovaAnneke Van Der WaltSara EichauRobert HydeNolan CampbellKarthik BodhinathanTim Spelmannull null

Published in: Therapeutic advances in neurological disorders (2024)

Early initiation of natalizumab produced long-term benefits in relapse outcomes in comparison with BRACETD, regardless of a subsequent escalation in therapy.

Keyphrases

multiple sclerosis
stem cells
open label
type diabetes
randomized controlled trial
metabolic syndrome
study protocol
weight loss